An informal progress meeting of the project was held in Honolulu (Hawaii) the past 30th of April, coinciding with the presence of many of the IMCUSTOMEYE partners at the ARVO 2018 Annual Meeting, the largest gathering of eye and vision researchers in the world.
The partners present at the meeting were Instituto Oftalmológico Fernández-Vega, Polish Academy of Science, Oculus Gmbh, IROC Science and CSIC. The meeting started with the presentation of Judith Birkenfeld's poster (“Assessment of ocular mechanical resonances using phase-sensitive OCT and frequency-domain air puff stimulation”), followed by a team discussion to follow up on the different action items, technical advances and administrative and logistical aspects of the IMCUSTOMEYE project for the following months.
The kick-off meeting of the H2020 Innovation Action IMCUSTOMEYE has taken place this week at CSIC led by Prof. Susana Marcos, researcher of the Institute of Optics (CSIC).
The IMCUSTOMEYE project will develop a new optical imaging system that will allow to obtain biomarkers to improve diagnosis of certain ocular pathologies such as glaucoma and keratoconus, and the development of customize treatments such as refractive surgery, cataract surgery and corneal treatments. Nowadays the diagnosis of corneal conditions and the selection of patients for refractive surgery are performed based on purely morphological effects (asymmetries in the cornea, corneal thickness). The new instrument will provide biomechanical parameters, which will allow to plan treatments based on the prediction of the corneal response (for example, to incisions or corneal implants). IMCUSTOMEYE will develop new diagnostic paradigms for these vision-threatening conditions.
The IMCUSTOMEYE consortium consists of 10 partners, from 6 different countries and different fields, academic, clinical and industrial: National University of Ireland, Polish Academy of Science, University of Liverpool, University College London-Moorfields Eye Hospital, Instituto Oftalmológio Fernandez Vega, Oculus Gmbh, 2EyesVision SL, IROC Science, Optimo Medical AG. During the kick-off meeting the partners presented their research activities and expected contributions to the project, and hold 10 round table discussions on technical aspects of the project, IP handling, and commercialization, among others.
The IMCUSTOMEYE project, a competitive H2020 Innovation Action of the Photonics KET Program, has just been launched under the leadership of the Visual Optics and Biophotonics Laboratory (Institute of Optics, CSIC; Principal Investigator: Susana Marcos).
IMCUSTOMEYE will develop a novel non-invasive label-free imaging-based in-depth diagnostic tool to create a step change in the paradigm for diagnostics of vision-threatening conditions including keratoconus, myopia, glaucoma, cataract and presbyopia, some of which potentially lead to loss of independence and productivity, with an impact on their treatment. The prevalence of these conditions ranges between 0.05% (keratoconus) to 100% (presbyopia in population >50 yr), and increase with age. Current standards for diagnosis and therefore treatment rely on limited quantitative information preventing treatments to be customised for individual patient’s needs. The proposed in-depth diagnostic paradigm will make use of morphological, biomechanical and optical biomarkers acquired from a new imaging device, based on Optical Coherence Tomography. These will allow creating predictive customised eye models that can guide diagnosis and treatment of individual patients. The optimisation and customisation of diagnosis, which has not been possible before, are expected to lead to significant improvement in both the provision and cost of eye healthcare.
The consortium is formed by leading institutions and companies in optical imaging, ocular biomechanics and ophthalmology. Partners include Academic Institutions: University of Liverpool (UK), Institute of Physical Chemistry of the Polish Academy of Sciences (Poland), National University of Ireland, Galway (Ireland); Eye Hospitals: Instituto Oftalmológio Fernandez Vega (Spain), and University College London Institute of Ophthalmology and Moorfields Eye Hospital (UK) and companies: IROC Science to Innovation AG (Switzerland), 2EyesVision SL (Spain), Oculus Optikgeräte GmbH (Germany), Optimo Medical AG (Switzerland)
More information and updates of the project will be found at www.imcustomeye.eu and @IMCUSTOMEYE